Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15729280 | 0.84 | CA3 (0.48) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL30249992 | 0.82 | ALDH1A1 (0.64) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL179468 | 0.82 | ALDH1A1 (0.64) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL12732698 | 0.82 | ALDH1A1 (0.44) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL104056 | 0.79 | CA3 (0.52) | MEN1KMT2ACA9CA3CA6 | |
| SCHEMBL828570 | 0.78 | ALDH1A1 (0.46) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL29358687 | 0.78 | ALDH1A1 (1.00) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL50705 | 0.78 | ALDH1A1 (1.00) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL31411213 | 0.78 | ALDH1A1 (0.73) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL340013 | 0.78 | ALDH1A1 (0.73) | ALDH1A1HPGDALOX15HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122037020-A | Supported catalyst, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-4152529-A | Dealkylation of halogenated alkyl substituted phenols | UOP INC. (US) | 1979-05-01 | — | — | US | claimed |
| US-4122288-A | Hydrolysis of alkyl substituted dihalobenzene compounds | UOP INC. (US) | 1978-10-24 | — | — | US | claimed |
| CN-122037020-A | Supported catalyst, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| CN-112679635-B | Preparation method of supported metallocene catalyst and catalyst prepared by preparation method | 中国石油化工股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20090137611-A1 | Fungicide N-Cyclopropyl-Sulfonylamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137611-A1 | Fungicide N-Cyclopropyl-Sulfonylamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2009-05-28 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-20 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-4152529-A | Dealkylation of halogenated alkyl substituted phenols | UOP INC. (US) | 1979-05-01 | — | — | US | disclosed |
| US-4152529-A | Dealkylation of halogenated alkyl substituted phenols | UOP INC. (US) | 1979-05-01 | — | — | US | disclosed |
| US-4122288-A | Hydrolysis of alkyl substituted dihalobenzene compounds | UOP INC. (US) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | MTOR, PI4KA, PIK3CA | ALDH1A1 4725/4885HPGD 4128/4885ALOX15 2761/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | ALDH1A1 2457/4885HPGD 2554/4885ALOX15 2558/4885 |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 3193/4885HPGD 3127/4885ALOX15 4809/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | ALDH1A1 2702/4885HPGD 2431/4885ALOX15 4081/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | ALDH1A1 3252/4885HPGD 916/4885ALOX15 1444/4885 |
| US-20090137611-A1 | Fungicide N-Cyclopropyl-Sulfonylamide Derivatives | CYP51A1, ERG28, CBR3 | ALDH1A1 2140/4885HPGD 4007/4885ALOX15 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.